Product logins

Find logins to all Clarivate products below.


Renal cell carcinoma (RCC) is a disease characterized by significant unmet need and, thus, opportunity. Its incidence is increasing in the major pharmaceutical markets, and many patients with early-stage disease suffer a recurrence. Moreover, the current therapies used to treat stage IV RCC can increase progression-free survival but have limited impact on prolonging overall survival. Interviewed experts are enthusiastic about the promise of an emerging class of drugs for RCC: immune checkpoint inhibitors.

Note: In April 2015, the RCC market was updated to reflect changes in our market assumptions for sorafenib (Bayer HealthCare/Onyx Pharmaceuticals’ Nexavar).

 

Related Market Assessment Reports

Report
Renal Cell Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens,…
Report
Renal Cell Carcinoma – Geographic Focus: China – China In-Depth – Renal Cell Carcinoma
The renal cell carcinoma (RCC) treatment landscape in China has evolved rapidly since the introduction of targeted therapies, including TKIs (Pfizer’s Sutent and Inlyta, Novartis’s Votrient,…
Report
Renal Cell Carcinoma | Disease Landscape & Forecast | G7 | 2024
The renal cell carcinoma (RCC) therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens…
Report
Renal Cell Carcinoma – Unmet Need – Unmet Need – Advanced or Metastatic Renal Cell Carcinoma (US/EU)
The treatment of advanced or metastatic renal cell carcinoma is dominated by immune checkpoint inhibitors (e.g., Merck & Co.’s Keytruda, BMS’s Opdivo and Yervoy) and small-molecule tyrosine…
Report
Renal Cell Carcinoma | Disease Landscape & Forecast | G7 | 2023
The renal cell carcinoma (RCC) therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens…